Cargando…
Comparison of Myelotoxicity and Nephrotoxicity Between Daily Low-Dose Cisplatin With Concurrent Radiation and Cyclic High-Dose Cisplatin in Non-Small Cell Lung Cancer Patients
AIM: Antineoplastic effect of cisplatin, the first line treatment in non-small cell lung cancer (NSCLC), is hindered by its nephrotoxicity and myelotoxicity. Both low-dose and high-dose regimens are used in the management of NSCLC. The aim of this study is to assess the risk on myelotoxicity and nep...
Autores principales: | Zazuli, Zulfan, Kos, Renate, Veltman, Joris D., Uyterlinde, Wilma, Longo, Cristina, Baas, Paul, Masereeuw, Rosalinde, Vijverberg, Susanne J. H., Maitland-van der Zee, Anke-Hilse |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332698/ https://www.ncbi.nlm.nih.gov/pubmed/32670072 http://dx.doi.org/10.3389/fphar.2020.00975 |
Ejemplares similares
-
Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review
por: Zazuli, Zulfan, et al.
Publicado: (2018) -
The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition
por: Zazuli, Zulfan, et al.
Publicado: (2020) -
Outcome Definition Influences the Relationship between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients
por: Zazuli, Zulfan, et al.
Publicado: (2019) -
Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation Study
por: Zazuli, Zulfan, et al.
Publicado: (2021) -
Evaluating dose of cisplatin responsible for causing nephrotoxicity
por: Higuchi, Kyouko, et al.
Publicado: (2019)